Os efeitos dos estrogênios conjugados equinos e do tamoxifeno na histomorfologia da glândula tireóide de ratas by Araujo, Luiz Felipe Bittencourt de et al.
321
CLINICS 2006;61(4):321-26
Department of Obstetrics and Gynecology, University of São Paulo Medical
School, São Paulo, Brazil. Department of Ginecology, Federal University os
São Paulo, São Paulo, Brazil.
Email: jsoares415@hotmail.com
Received for publication on January 27, 2006
Accepted for publication on March 28, 2006
ORIGINAL RESEARCH
EFFECT OF CONJUGATED EQUINE ESTROGENS
AND TAMOXIFEN ADMINISTRATION ON THYROID
GLAND HISTOMORPHOLOGY OF THE RAT
Luiz Felipe Bittencourt de Araujo, José Maria Soares Jr, Ricardo Santos Simões,
Pedro Luiz Calió, Ricardo Martins Oliveira-Filho, Manuel de Jesus Simões,
Mauro Abi Haidar, Edmund C. Baracat
Araujo LFB, Soares Jr JM, Simões RS, Calió PL, Oliveira-Filho RM, Simões MJ, Haidar MA, Baracat EC. Effect of
conjugated equine estrogens and tamoxifen administration on thyroid gland histomorphology of the rat. Clinics.
2006;61(4):321-26.
OBJECTIVE: The aim of this study was to evaluate the action of the conjugated equine estrogens and tamoxifen on the morphology
of thyroid gland in ovariectomized (OVx) rats.
METHODS: Conjugated equine estrogens (CEE), clinically used as estrogen therapy, is a complex formulation containing multiple
estrogens that decrease menopausal symptoms. Thirty ovariectomized rats were randomly divided into 3 treatment groups: GI,
vehicle (propylene glycol); GII, CEE 200 µg/kg per day; and GIII, tamoxifen 1 mg/kg per day. Another group of 10 rats with intact
ovaries (GIV) was included, treated with the vehicle, and sacrificed during estrous. All animals were treated by gavage for 50
days, after which they were sacrificed. Blood samples were collected, and the thyroid was removed for morphological analysis
and PCNA evaluation through immunohistochemical study.
RESULTS: The thyroid follicular cell height was increased in animals treated with CEE (14.90 ± 0.20 μm), with TAM (14.90 ±
0.10 μm), and in rats with intact ovaries (15.10 ± 0.50 μm) in comparison to that of the vehicle group (9.90 ± 0.20 μm) (P < 0.001).
The follicular area was larger in the CEE (2,225 ± 51 μm2) and TAM (2,127 ± 67 μm2) groups compared to that of the vehicle
group (5,016 ± 53 µm2). The levels of T4 and T3 in rats treated with CEE, with Tamoxifen and in rats with intact ovaries, were
higher than those those in the vehicle group (P < 0.001). The PCNA index in the vehicle group was lower than in other groups.
CONCLUSION: Our data suggest that estrogen and tamoxifen administration has a proliferative effect on the thyroid.
KEYWORDS: Estrogen. Tamoxifen. Thyroid. Ovariectomized rats, Morphometrics.
INTRODUCTION
There is a great wealth of published data on the value of
estrogen therapy in alleviating menopausal symptoms, such
as hot flashes and insomnia, and in preventing chronic prob-
lems, including urogenital atrophy and osteoporosis.1,2. Al-
though some studies have demonstrated influences of
estrogens on the development, physiology, and pathology of
the thyroid gland, questions about the effects of estrogen re-
placement therapy on the thyroid gland remain unan-
swered3,6. Additionally, thyroid diseases are more common
in women.7 Conjugated equine estrogens (CEE), clinically
used as estrogen therapy, is a complex formulation (obtained
from pregnant mares’ urine) containing multiple estrogens,
including several not secreted by human ovaries, as well as
other biologically active steroids. These hormones stimulate
the proliferation of tissue with estrogen receptors.8
Hypothyroid women who are under treatment with thy-
roxine (T4) are reported to experience changes in the cir-
culating levels of T4 and TSH upon starting estrogen re-
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placement therapy. In fact, under these conditions, there
are increased titers of thyroxine-binding globulin leading
to an enhanced fraction of bound thyroxine and, conse-
quently, a feedback-driven increase of TSH levels. Since
the adaptation is somewhat insufficient, there is an in-
creased need for thyroxine in these women taking hor-
mone replacement therapy.4
In addition, some experimental studies have shown that
estrogens might up-regulate their own receptors in the thy-
roid and thereby influence the growth of the gland and the
proliferation of thyrocytes.5,9
Tamoxifen is a selective estrogen receptor modulator
(SERM) with either estrogen agonistic or antagonistic ac-
tivities, depending upon the particular target organ. It is a
valuable therapeutic agent, with applications in the treat-
ment and prevention of estrogen-responsive breast cancer.10
The efficacy of tamoxifen in preventing recurrence and fa-
talities from breast cancer when used as an adjuvant treat-
ment has been well-established.10 Additionally, the recent
introduction of SERMs may further increase the safety of
hormone replacement therapy, but the effects of these drugs
on the thyroid gland morphology are not fully understood.
Therefore, the aim of this study was to study the effects of
tamoxifen and estrogens on thyroid gland morphology of
ovariectomized rats.
METHOD
All procedures involving rats were approved by the Fed-
eral University of São Paulo Research Ethics Committee;
animal handling conformed to the APS Guiding Principles
for The Care and Use of Animals. Adult female (3 months)
Wistar rats (180-210 g body weight) were kept under a
14:10 h light:dark cycle (lights on at 08:00 am) at 23°C
and were fed a standard diet and tap water ad libitum.
Thirty animals were bilaterally ovariectomized (OVx). One
month later, the rats were randomly divided into 3 treat-
ment groups: GI, vehicle (propylene glycol); GII, conju-
gated equine estrogens (CEE) 200 µg/kg per day; and GIII,
tamoxifen 1 mg/kg per day. Another group of 10 rats with
intact ovaries and treated with vehicle (GIV) was included
from which vaginal smears were daily collected for iden-
tifying the phase of estrous cycle. All animals were treated
once a day by oral route (gavage) for 50 consecutive days.
Then, the rats were weighed and sacrificed by decapita-
tion, trunk blood was collected and centrifuged. Serum was
separated and stored at –20oC until assay for hormone level
determinations. The animals in GIV were sacrificed only
during estrous. Thyroid glands were carefully dissected out,
weighed, and immediately fixed in Bouin’s solution for 24
hours. Every fixed gland was dehydrated in graded alco-
hol, embedded in paraffin, sectioned at 4 µm, and stained
with hematoxylin and eosin for light microscopic analy-
sis. A section of the central portion of every lobe was se-
lected for analysis.11 For determination of the thyroid
follicular cell proliferation index, the sections were immu-
nohistochemically stained with anti-proliferating cell nu-
clear antigen (PCNA) antibody PC-10 (Dako, Denmark).
The PCNA-positive nuclei (PCNA-labeling index) in 1,000
cells of the follicular epithelium were counted and ex-
pressed as percentages of the total cell count.
Serum triiodothyronine (T3), thyroxine (T4), and thy-
roid stimulating hormone (TSH) were measured with ra-
dioimmunoassay kits, using respectively Coat-A-Count®
Canine T3 Kit (Diagnostic Products Co., CA), DPC Total
T4 Kit (Diagnostic Products Co., CA), and Rat Thyroid
Stimulating Hormone (rTSH) [125I] assay system
(Amersham Pharmacia Biotech, UK), respectively. Coef-
ficients of variation for the TSH assays were 9.6% within
assay and 4.9% between assays. This assay system has been
used and validated in other experimental studies.12-14
The morphometric measurements were performed us-
ing digitalized images obtained directly from the light mi-
croscope via a video camera and stored on magnetic me-
dia. Measurements were automatically processed using
Imagelab Softium® software (São Paulo, Brazil). For each
sample, the areas (follicular and colloidal) from 200 folli-
cles and the height of 4 cells per follicle (400 per sample)
were measured at a magnification of 400x. Two different
observers independently evaluated the images, with simi-
lar resutls. Both of them were blind to the analyzed groups.
Statistical analysis
Data from morphometry and hormone level
determinations are given as mean ± standard error of the
mean (SEM); the results were analyzed using 1-way
ANOVA followed by the Newmann-Keuls multiple com-
parison test, with the level of significance set at P < 0.05.
RESULTS
Under light microscopy, in the control ovariectomized
group (GI, treated with propylene glycol), the thyroid gland
had a thin connective tissue capsule around it. Also, fine
septa emerging from the capsule divided the gland into nu-
merous small ill-defined lobules with large and distended
follicles, which in turn were often lined by cuboidal epi-
thelium. The colloid deposited therein appeared heavily
stained and often filled up the entire lumen without con-
spicuous peripheral vacuoles (Fig. 1). The luminal surface
of the follicular cells was flattened. In addition, each fol-
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licle was surrounded by a delicate network of reticular fi-
bres and blood capillaries.
Clear-cut differences in thyroid gland structure were no-
ticed between the hormone-treated groups (conjugated equine
estrogens and tamoxifen, GII and GIII, respectively) and the
ovariectomized control group (GI). The connective tissue cap-
sule around the thyroid gland in GII (conjugated equine
estrogens) and in GIII (tamoxifen) was thicker than in GI (ova-
riectomized rat). Also, the lobules presented small and par-
tially collapsed follicles with a reduction in the amount of col-
loid in GII (conjugated equine estrogens), in GIII (tamoxifen),
and in GIV (rats with intact ovaries) as compared to the
amount in GI (ovariectomized rats). Additionally, the follicular
epithelium was seen to be columnar with larger nuclei in GII
(estrogen treatment), in GIII (tamoxifen treatment), and in GIV
(with intact ovaries) than in GI (ovariectomized rats, Fig. 1).
The reticular fibers and blood capillaries in GII (conjugated
equine estrogens) and in GIII (tamoxifen) were more devel-
oped than in GI (ovariectomized), but not compared to those
in GIV (rats with intact ovaries).
The thyroid weight in GI (ovariectomized rats treated
with vehicle) was lower than in other groups (Table 1). The
morphometric analysis showed that the follicular cell
heights in GII (estrogen treatment), in GIII (tamoxifen treat-
ment), and GIV (with intact ovaries) were higher than in
GI (P < 0.001), and the measurements in GII (estrogen
treatment) produced values that were essentially indistin-
guishable from those in GIII (tamoxifen treatment) and in
GIV (with intact ovaries) (Table 1). Also, the follicular and
colloid areas of GII (estrogen treatment) and of GIII
(tamoxifen treatment) were smaller than those of GI (ova-
riectomized rats treated with vehicle) (P < 0.001), but not
significantly different from each other in this regard. Ad-
ditionally, the PCNA index in GI (ovariectomized rats with
vehicle) was lower than in other groups (Fig. 2).
The levels of TSH in GII (estrogen treatment), in GIII
(tamoxifen treatment), and in GIV (intact ovaries) were
lower than those in GI (ovariectomized rats treated with
vehicle, P < 0.001, Table 1). The levels of T3 and T4 in
GII (estrogen treatment), in GIII (tamoxifen treatment),
and in GIV (intact ovaries) were higher than those in GI
(ovariectomized rats treated with vehicle, P < 0.001, Ta-
ble 1).
DISCUSSION
Tamoxifen is a triphenylethylene derivative commonly
used in the treatment of breast cancer.15-18 This drug is
known to have various biological effects ranging from com-
plete estrogen antagonism to pure estrogen agonism, de-
pending upon its concentration, the sex of the animal, and
the target organ.15,19,20
Table 1- Morphological and functional thyroid data of adult ovariectomized rats treated for 50 days with conjugated
equine estrogens (GII), tamoxifen (GIII), or drug vehicle (GI). (mean ± SEM)
Treatments
GI (vehicle) (n = 10) GII (estrogen)(n = 10) GIII (tamoxifen)(n = 10) GIV (estrous)**(n = 10)
Body weight (g) 270.50 ± 4.90 226.70 ± 4.30a 217.50 ± 5.10a 228.00 ± 3.70a
Thyroid weight (g) 10. 80 ± 0.60 18.80 ± 1.50 a 16.10 ± 1.70a 15.60 ± 1.60a
T/B 3.98 ± 0.23 8.28 ± 0.66a 7.39 ± 0,78b 6.84 ± 0.69c
Cell height (μm) 9.90 ± 0.20 14.9 ± 0.20a 14.9 ± 0.10a 15.1 ± 0.50
Follicular area (μm2) 5.016 ± 53 2.225 ± 5a 2.127 ± 67a 3.112 ± 41
Colloid area (μm2) 4.328.10 ± 174.90 1.303.90 ± 64.90a 1.325.20 ± 86.10a 1.404.00 ± 78.40a
PCNA 0.014 ± 0.006 0.086 ± 0.013a 0.098 ±0.01a 0.096 ± 0.008a
Hormonal analyses*
TSH (ng/mL) 6.65 ± 0.17 4.09 ± 0.15a 3.92 ± 0.23a 3.42 ± 0.15a
T3 (ng/mL) 1.44 ± 0.05 1.90 ± 0.06b 2.01 ± 0.08a 2.22 ± 0.15a
T4 (µg/mL) 3.11 ± 0.08 7.46 ±0.45a 8.47 ± 0.47a 8.65 ± 0.32a
T/B = thyroid weight/body weight ratio x105; aP <0.001 compared to GI; bP < 0.01 compared to GI; cP < 0.05 compared to GI; n = number of animals.
*the means of 3 assays; **non-ovariectomized control, treated with vehicle, sacrificed during estrous
Figure 1- Photomicrograph of the central area of the right thyroid lobe of
ovariectomized rats: A. the follicular epithelium is cuboidal with small nuclei
(GI); B. the follicular epithelium is columnar epithelium with large nuclei
(GII); C. the follicular epithelium is columnar epithelium with large nuclei
(GIII); D. the follicular epithelium is columnar epithelium with large nuclei
(GIV) (HE, x 1100).
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In humans and rats, tamoxifen is predominantly
antiestrogenic with residual estrogenic activities,15 except in
the uterus21 and thyroid gland, as demonstrated in this study.
In fact, the results of the present investigation showed
that the thyroid gland was significantly affected by treat-
ment with estrogen or tamoxifen, showing an increased
follicular cell height and decreased follicular and colloi-
dal areas as compared to controls. Also, the PCNA index
was increased in treated groups compared to the vehicle-
treated group. These histological features were generally
correlated to the thyroidal functional status,22 since the se-
rum T3 and T4 levels were enhanced in animals treated
with estrogen or tamoxifen as compared to the vehicle-
treated controls.
The effects of estrogens and tamoxifen on thyroid gland
have been the subject of many investigations, but several
aspects of these effects are still unknown. The presence of
estrogen receptors in the thyroid suggests a direct action
of estrogens and estrogenic-stimulating drugs on the
gland.23-25 Also, some experiments using thyrocytes in vitro
have demonstrated that estrogen has a definite role in the
proliferation of these cells.5,6,26,27
However, some studies have shown that the effects of
estrogen and tamoxifen on thyroid gland may be rather in-
direct, as a consequence of increased serum levels of thy-
roxine-binding globulin (TBG) and the associated changes
in thyroid function.28-31 Other data suggests that the action
of these drugs may be directly on the pituitary through the
release of TSH.32-35 Donda et al13 showed that estrogen had
a stimulatory effect on pituitary function and release of
TSH. However, in our study, an increase in TSH levels was
detected after oophorectomy compared to that in the estrous
phase and treated groups. One explanation may be the nega-
tive feedback of T3 and T4 hormones on TSH release af-
ter the hormonal treatment.36 In addition, another study
showed that estrogen may interact with TSH and thus play
a role in thyroid function; conversely, sex steroids may in
turn modulate TSH-induced cell proliferation.37
As a matter of fact, estradiol administration to female
rats is able to reduce the TSH levels.33 Also, another report
using pituitary cells in vitro suggested that estradiol was
physiologically important in maintaining normal responses
to thyrotropin-releasing hormone (TRH) in female rats.38
Regardless of the mechanism, our data suggest that
tamoxifen may be an agonist to estrogen receptors in the
rat thyroid leading to proliferation of thyrocytes and in-
creasing T3 and T4 levels. Although the extrapolation of
these results to humans should be interpreted with caution,
it is highly conceivable that the monitoring of thyroid func-
tion may be important for those patients who are or are
going to be under estrogen or tamoxifen therapy.
Figure 2- Photomicrograph of PCNA reaction in the central area of the right
thyroid lobe of ovariectomized rats: A. ovariectomized animals treated with
vehicle (GI); B. ovariectomized animals treated with conjugated equine
estrogens (GII); C. ovariectomized animals treated with tamoxifen (GIII);
D. animals in estrous phase treated with vehicle (GIV). The arrows show
the positive reaction. (HE, x 1100).
RESUMO
Araujo LFB, Soares Jr JM, Simões RS, Calió PL, Oliveira-
Filho RM, Simões MJ, Haidar MA, Baracat EC. Os efeitos
dos estrogênios conjugados equinos e do tamoxifeno na
histomorfologia da glândula tireóide de ratas. Clinics.
2006;61(4):321-26.
OBJETIVO: Avaliar a ação dos estrogênios conjugados
eqüinos e do tamoxifeno na histomorfologia da tireóide
de ratas.
MÉTODO: Estrogênios conjugados eqüinos são ministrados
clinicamente como terapia estrogênica e contêm formulação
complexa com muitos tipos de estrogênios que diminuem
os sintomas da pós-menopausa. Trinta ratas adultas
ooforectomizadas foram divididas aleatoriamente em três
grupos: GI – veículo (propilenoglicol); GII - ECE 200 µg/
Kg por dia; e GIII – TAM 1 mg/Kg por dia. Acrescentou-se
ainda um grupo de 10 animais com os ovários intactos e
tratados com veículo (GIV). Todos os animais foram tratados
por gavagem durante 50 dias consecutivos, ao final foram
coletadas amostras do sangue e a tireóide removida e
processada para análise morfológica e imunohistoquímico
para avaliar o PCNA.
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RESULTADOS: A maior altura das células foliculares foi
observada nos animais tratados com ECE (14,90 ± 0,20
μm), TAM (14,90 ± 0,10 μm) e no grupo com ovários
intactos (15,10 ± 0,50 μm), comparando-se aos controles
ovariectomizados (GI) (9,90 ± 0,20 μm) (p<0,001). A maior
área folicular foi detectada nos grupos tratados com ECE
(2.225 ± 51 μm2) e com TAM (2.127 ± 67 μm2), comparado
ao veículo (5.016 ± 53 μm2) em animais ooforectomizados.
Os níveis de T4 e T3 nos grupos tratados com ECE, com
TAM e no grupo com ovários intactos foram maiores do
que no grupo tratado com veículo (p<0,001). O índice do
PCNA no grupo tratado com veículo foi menor do que em
todos os outros grupos.
CONCLUSÃO: Nossos dados sugerem que a
administração de ECE e TAM resulta em atividade
proliferativa na tireóide.
UNITERMOS: Estrogênio. Tamoxifeno. Tireóide. Ratas,
Morfologia.
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